<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182272</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000682840</org_study_id>
    <secondary_id>FRE-GERCOR-D09-1-BIOSHARE</secondary_id>
    <secondary_id>EUDRACT-2009-018058-44</secondary_id>
    <secondary_id>EU-21058</secondary_id>
    <nct_id>NCT01182272</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Proof-of-Concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib Along With Pathological and Molecular Changes in Tumor Samples From Patients With Resectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well sorafenib tosylate works in treating&#xD;
      patients with liver cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess anti-tumor activity of neoadjuvant sorafenib tosylate in tumor samples from&#xD;
           patients with resectable hepatocellular carcinoma (HCC).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize pathologic findings in sorafenib tosylate pre-treated patients&#xD;
           undergoing surgical resection for HCC: 1-2 core tumor biopsies will be performed prior&#xD;
           to treatment and at day 35.&#xD;
&#xD;
        -  To evaluate the number of R0 resections in these patients.&#xD;
&#xD;
        -  To correlate pathological biomarker changes in resected tumors after 4-week treatment&#xD;
           with sorafenib tosylate in comparison with biopsies obtained prior to treatment in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate plasma biomarkers, including PIGF, VEGF-A, VEGF-C, sVEGFR2, sVEGFR3, sKIT,&#xD;
           IL-6, Ang2, IL-8, bFGF, AFP, collagen 4, endostatin, thrombospondin, TSP-1 and&#xD;
           angiostatin, and CXCL12 at baseline, day 28, and the day before surgery.&#xD;
&#xD;
        -  To identify potential biomarkers of sensitivity and/or resistance on biological and&#xD;
           pathological samples of these patients (exploratory).&#xD;
&#xD;
        -  To characterize the safety profile of sorafenib tosylate in these patients.&#xD;
&#xD;
        -  To assess the tolerance of liver resection after sorafenib tosylate treatment of these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sorafenib tosylate twice daily on days 1-28 in the absence of&#xD;
      unacceptable toxicity. Approximately 7 days after completion of sorafenib tosylate therapy,&#xD;
      patients undergo liver resection.&#xD;
&#xD;
      Blood and tissue specimens are collected periodically for laboratory and biomarker&#xD;
      assessments. Biomarkers include both molecular markers investigating the direct antitumor&#xD;
      effects of sorafenib tosylate against cancer cells vs the effects of the drug on&#xD;
      angiogenesis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up on day 50 and at 3 months after&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antiangiogenic effects of sorafenib tosylate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Significant pathological changes</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic findings in sorafenib tosylate pre-treated patients undergoing surgical resection for hepatocellular carcinoma</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of R0 resections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between baseline patient characteristics, cancer biomarkers, and outcome variables and resected tumors</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma biomarkers at baseline, day 28, and the day before surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of sorafenib tosylate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of liver resection after sorafenib tosylate treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma (HCC)&#xD;
&#xD;
               -  Fibrolamellar or mixed histology allowed&#xD;
&#xD;
               -  No cholangiocarcinoma or other tubal disease&#xD;
&#xD;
          -  Must be eligible for conservative hepatic resection or liver resection with curative&#xD;
             intent&#xD;
&#xD;
          -  No cirrhosis with Child-Pugh score &gt; 7&#xD;
&#xD;
          -  Chronic liver disease without liver insufficiency and without portal liver&#xD;
             hypertension allowed&#xD;
&#xD;
          -  No known history or presence of metastatic brain or meningeal tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  WBC &gt; 3,000/µL&#xD;
&#xD;
          -  ANC &gt; 1,500/µL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper normal limit (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 5 times UNL&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 2 times ULN&#xD;
&#xD;
          -  PT/INR/PTT &lt; 1.5 times UNL&#xD;
&#xD;
          -  Amylase and lipase &lt; 1.5 times ULN&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Body mass index 18.5-30 kg/m^2 (WHO normal range: 18.5-25 kg/m^2)&#xD;
&#xD;
          -  Able to swallow oral compound&#xD;
&#xD;
          -  No criterion for unresectability or medical condition that contraindicates surgical&#xD;
             resection&#xD;
&#xD;
          -  No serious concurrent systemic disorder incompatible with the study, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Uncontrolled hypertension (i.e., BP &gt; 150/100 mm Hg despite optimal therapy)&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Active alcoholism&#xD;
&#xD;
          -  No prior medical disorder, including any of the following:&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmics (excluding beta-blockers or&#xD;
                  digoxin for chronic atrial fibrillation)&#xD;
&#xD;
               -  Active coronary artery disease or ischemia&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  NYHA class III-IV congestive heart failure&#xD;
&#xD;
               -  Pulmonary embolism within the past 6 months&#xD;
&#xD;
               -  Gastrointestinal bleeding within the past 6 months&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years, except basal cell or squamous cell&#xD;
             skin carcinoma or cured in situ cervical carcinoma&#xD;
&#xD;
          -  No history or concurrent seizure disorder requiring medications (e.g., antiepileptic&#xD;
             drugs)&#xD;
&#xD;
          -  No history of HIV infection, or chronic hepatitis B or C&#xD;
&#xD;
          -  No active clinically serious bacterial or fungal infection (i.e., grade 2 CTCAE v. 3)&#xD;
&#xD;
          -  No condition that is unstable or could jeopardize the safety of the patient and&#xD;
             his/her compliance with the study&#xD;
&#xD;
          -  No substance abuse or medical, psychological, or social condition that could interfere&#xD;
             with adherence to the study&#xD;
&#xD;
          -  No known or suspected allergy to the investigational agent or to any agent given&#xD;
             concurrently&#xD;
&#xD;
          -  No presence of asthenia or rash &gt; CTC grade 1 at enrollment&#xD;
&#xD;
          -  Must be registered in a national health-care system&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior orthotopic liver transplantation&#xD;
&#xD;
          -  Not a candidate for orthotopic liver transplantation&#xD;
&#xD;
          -  No prior systemic or loco-regional treatment for HCC&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  No treatment with any other investigational medicinal product within the past 28 days&#xD;
&#xD;
          -  No concurrent treatment with full-dose anticoagulants&#xD;
&#xD;
               -  Deep-vein or catheter-associated thrombosis prophylaxis allowed&#xD;
&#xD;
               -  Warfarin or heparin therapy allowed if the coagulation parameters were within the&#xD;
                  acceptable ranges prior to initiation of anticoagulant therapy&#xD;
&#xD;
          -  No concurrent or chronic co-administration of CYP3A4 inducers (e.g., rifampin,&#xD;
             Hypericum perforatum, phenytoin, carbamazepine, phenobarbital, or dexamethasone)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine Faivre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Beaujon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-1-4087-5614</phone>
      <email>sandrine.faivre@bjn.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

